About this trial
To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation.
Eligibility criteria
Qualifiers
Age ≥18 years;
Major neurologic deficits: 6≤NIHSS≤20;
Missing recanalization therapy (IVT or EVT) or progressive stroke, which was defined as symptoms worsen in 48 hours (an increase in NIHSS more than 4);
Premorbid mRS 0 or 1;
Disqualifiers
Modified Rankin Score >2 caused by a history of prior stroke;
Patients who underwent intravenous thrombolysis or Endovascular treatment;
Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia ( <80000/mm3;
Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;
Trial design
Treatments tested in this trial
- Intra-arterial administration of neuroprotective agents
Treatment groups
Sponsors and collaborators
Hui-Sheng Chen
Lead sponsor
General Hospital of Shenyang Military Region
Sponsor institution